Modalis Therapeutics Corporation

Company Profile

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

17

Website

modalistx.com

Country

Japan

Exchange

Tokyo

Chuo, Japan

Modalis Therapeutics provides the research and development of therapeutics to treat patients with serious genetic disorders. The company is developing therapies for genetic diseases using its proprietary CRISPR-GNDM an epigenome editing technology that combines dCas9.

It also develops various therapeutics for muscle disorders, cardiomyopathy, and CNS disorders. Incorporated in 2016 and headquartered in Chuo, Japan, Modalis Therapeutics was formerly known as EdiGENE Corporation before rebranding in August 2019.

Key Stats

52-Week Range

¥30.00¥97.00

Beta0.40

Trailing P/EN/A

Forward P/E1.47

Trailing EPS-27.86

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.